NCT02954874 2026-06-03Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast CancerNational Cancer Institute (NCI)Phase 3 Active not recruiting1,155 enrolled
NCT04849871 2026-05-06BreaStBRTWashington University School of MedicinePhase NA Active not recruiting134 enrolled